SCHEMBL3785072

SCHEMBL3785072

CC(C)[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MME P08473 1/20 0.41
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40
PLA2G2A P14555 1/20 0.39
PLA2G5 P39877 1/20 0.39
POLB P06746 1/20 0.39
BHMT Q93088 1/20 0.38
ENPEP Q07075 5/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
ERAP2 Q6P179 1/20 0.37
BACE1 P56817 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30494619 1.00 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MMEDPP4DPP8
SCHEMBL30494781 1.00 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MMEDPP4DPP8
SCHEMBL3785069 1.00 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MMEDPP4DPP8
SCHEMBL30567423 0.96 BACE1 (0.40) SMN1; SMN2ALDH1A1MMEDPP4DPP8
SCHEMBL29578129 0.96 BACE1 (0.40) SMN1; SMN2ALDH1A1MMEDPP4DPP8
SCHEMBL31181173 0.92 ENPEP (0.44) ENPEPBACE1
SCHEMBL30462197 0.89 PDCD1LG2 (0.44) MMEDPP4DPP8DPP9ENPEP
SCHEMBL31307239 0.88 BACE1 (0.45) MMEBACE1
SCHEMBL8526326 0.87 PDCD1LG2 (0.48) MMEDPP4DPP8DPP9BHMT
SCHEMBL29531923 0.87 PDCD1LG2 (0.45) SMN1; SMN2ALDH1A1MMEDPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648799-A1 LIGAND-DRUG CONJUGATES Sun Pharma Advanced Research Company Ltd (IN) 2025-11-19 EP claimed
EP-4605407-A2 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS Endevica Bio, Inc. (US) 2025-08-27 EP claimed
CN-119523057-A Method for improving taste dipeptide content in salted fish 海南大学三亚研究院 2025-02-28 CN claimed
CN-118409095-A Metabolic markers for diagnosing the extent of coronary artery stenosis and uses thereof 哈尔滨脉图精准技术有限公司 2024-07-30 CN claimed
WO-2024150132-A1 LIGAND-DRUG CONJUGATES SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2024-07-18 WO claimed
WO-2024086381-A2 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS ENDEVICA BIO, INC. (US) 2024-04-25 WO claimed
CN-117838878-A Antibody-STING agonist conjugates and their use in immunotherapy 免疫传感器治疗股份有限公司 2024-04-09 CN claimed
CN-115353551-B Oat-derived GLP-1 secretion-promoting oligopeptide and preparation method and application thereof 上海理工大学 2024-01-26 CN claimed
CN-117074700-A Metabolic markers for diagnosing the extent of coronary artery stenosis and uses thereof 哈尔滨脉图精准技术有限公司 2023-11-17 CN claimed
CN-117015381-A Novel steroid payloads, steroid linkers, ADCs containing the same and uses thereof 伊穆奈克斯特股份有限公司 2023-11-07 CN claimed
CN-115047120-B Method for analyzing and detecting dansyl chloride derivative of dipeptide substances in white spirit Daqu 贵州茅台酒股份有限公司 2023-08-29 CN claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
EP-4114417-A2 THERAPEUTIC AGENTS AND CONJUGATES THEREOF Beijing Xuanyi Pharmasciences Co., Ltd. (CN) 2023-01-11 EP claimed
CN-115427051-A Therapeutic agents and conjugates thereof 北京轩义医药科技有限公司 2022-12-02 CN claimed
CN-115353551-A Oat-derived GLP-1 secretion promoting oligopeptide and preparation method and application thereof 上海理工大学 2022-11-18 CN claimed
CN-115047120-A Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu 贵州茅台酒股份有限公司 2022-09-13 CN claimed
US-20220257789-A1 ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS EXELIXIS, INC. 2022-08-18 US claimed
EP-3999118-A1 ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY Immunesensor Therapeutics, Inc. (US) 2022-05-25 EP claimed
EP-3994150-A1 ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS Iconic Therapeutics, Inc. (US) 2022-05-11 EP claimed
CN-114222752-A Anti-tissue factor antibody-drug conjugates and related methods 伊科尼克治疗公司 2022-03-22 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220257789-A1 ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS F3, F13B, TFPI SMN1; SMN2 3706/4885ALDH1A1 1620/4885MME 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.